• This record comes from PubMed

MicroRNA-15a expression measured in urine samples as a potential biomarker of renal cell carcinoma

. 2018 May ; 50 (5) : 851-859. [epub] 20180316

Language English Country Netherlands Media print-electronic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/pmid29549624
Links

PubMed 29549624
DOI 10.1007/s11255-018-1841-x
PII: 10.1007/s11255-018-1841-x
Knihovny.cz E-resources

INTRODUCTION: Currently, there is no accurate diagnostic molecular biomarker for renal cell carcinoma (RCC). The aim of this study was to assess the expression of microRNA-15a (miR-15a) in urine of patients with RCC and to evaluate its potential as a diagnostic molecular biomarker. MATERIALS AND METHODS: In total, 67 patients with solid renal tumors were enrolled: clear-cell RCC (ccRCC, n = 22), papillary RCC (pRCC, n = 16), chromophobe RCC (chRCC, n = 14), oncocytoma (n = 8), papillary adenoma (n = 2) and angiomyolipoma (n = 5). MiRNA-15a expression levels measurement in urine were performed using qPCR. Urine of 15 healthy volunteers without kidney pathology was used as control. RESULTS: We observed a difference in mean miR-15a expression values in groups of pre-operative patients with RCC, benign renal tumors and healthy persons (2.50E-01 ± 2.72E-01 vs 1.32E-03 ± 3.90E-03 vs 3.36E-07 ± 1.04E-07 RFU, respectively, p < 0.01). There was no difference in miR-15a expression between ccRCC, pRCC and chRCC (p > 0.05). Direct association between RCC size and miR-15a expression values was obtained (Pearson correlation coefficient-0.873). On the 8th day after nephrectomy, mean expression value in patients with RCC decreased by 99.53% (p < 0.01). MiR-15a expression differentiated RCC from benign renal tumors with 98.1% specificity, 100% sensitivity at a cut-off value of 5.00E-06 RFU, with AUC-0.955. CONCLUSIONS: MiR-15a expression measured in urine may be used as diagnostic molecular biomarker for RCC.

See more in PubMed

Am J Nephrol. 2007;27(3):294-300 PubMed

J Urol. 2005 May;173(5):1690-4 PubMed

Am J Pathol. 2012 May;180(5):1787-97 PubMed

Transl Oncol. 2014 Apr;7(2):309-21 PubMed

Oncotarget. 2016 Jul 12;7(28):44350-44364 PubMed

Nat Immunol. 2010 Sep;11(9):799-805 PubMed

Int J Oncol. 2014 Jan;44(1):53-8 PubMed

BJU Int. 2013 Apr;111(4 Pt B):E146-51 PubMed

Can J Urol. 2015 Dec;22(6):8069-73 PubMed

Oncol Res. 2016;24(3):145-51 PubMed

Pathol Oncol Res. 2017 Jul;23 (3):689-698 PubMed

J Urol. 2008 Aug;180(2):510-3; discussion 513-4 PubMed

Cancer Biol Ther. 2014 Mar 1;15(3):329-41 PubMed

J Clin Oncol. 2009 Jun 1;27(16):2645-52 PubMed

Methods Mol Biol. 2015;1218:439-63 PubMed

Tumour Biol. 2014 May;35(5):4057-66 PubMed

Anticancer Res. 2015 Jan;35(1):123-7 PubMed

Cancer Res. 2009 Jan 1;69(1):65-74 PubMed

Urol Int. 2017;98 (2):156-161 PubMed

Int Urol Nephrol. 2017 Mar;49(3):541-550 PubMed

Br J Cancer. 2012 Sep 25;107(7):1131-7 PubMed

Int J Biochem Cell Biol. 2011 Nov;43(11):1537-49 PubMed

Eur Urol. 2017 May;71(5):719-722 PubMed

Biochim Biophys Acta. 2011 Oct;1813(10):1793-802 PubMed

BMC Cancer. 2014 Jan 15;14:25 PubMed

Eur Urol. 2011 May;59(5):721-30 PubMed

Clin Cancer Res. 2014 May 15;20(10):2617-30 PubMed

Arch Ital Urol Androl. 2009 Jun;81(2):107-12 PubMed

Int Urol Nephrol. 2018 May;50(5):973-982 PubMed

Find record

Citation metrics

    Archiving options